A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa A. Kujawski, Allen Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph E. Eid, Gregory M. Lubiniecki, Jean Pierre Issa

Research output: Contribution to journalArticle

Abstract

Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) may respond to treatment with epigenetic-modifying agents. Histone deacetylase inhibitors may synergize with hypomethylating agents. This phase 1 dose-escalation study was designed to determine the maximum tolerated dose, recommended phase 2 dose, safety and tolerability of vorinostat plus decitabine in patients with relapsed/refractory AML, newly-diagnosed AML, or intermediate- to high-grade MDS. Thirty-four patients received concurrent therapy with decitabine plus vorinostat and 37 received sequential therapy with decitabine followed by vorinostat. Twenty-nine patients had relapsed/refractory AML, 31 had untreated AML and 11 had MDS. The target maximum administered dose (MAD) of decitabine 20 mg/m2 daily for 5 d plus vorinostat 400 mg/d for 14 d was achieved for concurrent and sequential schedules, with one dose-limiting toxicity (Grade 3 QTc prolongation) reported in the sequential arm. Common toxicities were haematological and gastrointestinal. Responses were observed more frequently at the MAD on the concurrent schedule compared with the sequential schedule in untreated AML (46% vs. 14%), relapsed/refractory AML (15% vs. 0%) and MDS (60% vs. 0%). Decitabine plus vorinostat given concurrently or sequentially appears to be safe and well-tolerated. Concurrent therapy shows promising clinical activity in AML or MDS, warranting further investigation.

Original languageEnglish (US)
Pages (from-to)185-193
Number of pages9
JournalBritish Journal of Haematology
Volume167
Issue number2
DOIs
StatePublished - Oct 1 2014

Fingerprint

decitabine
Clinical Trials, Phase I
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Appointments and Schedules
Histone Deacetylase Inhibitors
Maximum Tolerated Dose
vorinostat
Therapeutics
Epigenomics

Keywords

  • Acute myeloid leukaemia
  • Combination therapy
  • Decitabine
  • Myelodysplastic syndrome
  • Vorinostat

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. / Kirschbaum, Mark; Gojo, Ivana; Goldberg, Stuart L.; Bredeson, Christopher; Kujawski, Lisa A.; Yang, Allen; Marks, Peter; Frankel, Paul; Sun, Xing; Tosolini, Alessandra; Eid, Joseph E.; Lubiniecki, Gregory M.; Issa, Jean Pierre.

In: British Journal of Haematology, Vol. 167, No. 2, 01.10.2014, p. 185-193.

Research output: Contribution to journalArticle

Kirschbaum, M, Gojo, I, Goldberg, SL, Bredeson, C, Kujawski, LA, Yang, A, Marks, P, Frankel, P, Sun, X, Tosolini, A, Eid, JE, Lubiniecki, GM & Issa, JP 2014, 'A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome', British Journal of Haematology, vol. 167, no. 2, pp. 185-193. https://doi.org/10.1111/bjh.13016
Kirschbaum, Mark ; Gojo, Ivana ; Goldberg, Stuart L. ; Bredeson, Christopher ; Kujawski, Lisa A. ; Yang, Allen ; Marks, Peter ; Frankel, Paul ; Sun, Xing ; Tosolini, Alessandra ; Eid, Joseph E. ; Lubiniecki, Gregory M. ; Issa, Jean Pierre. / A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. In: British Journal of Haematology. 2014 ; Vol. 167, No. 2. pp. 185-193.
@article{ecfab26eb6644a4daacc85e369727611,
title = "A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome",
abstract = "Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) may respond to treatment with epigenetic-modifying agents. Histone deacetylase inhibitors may synergize with hypomethylating agents. This phase 1 dose-escalation study was designed to determine the maximum tolerated dose, recommended phase 2 dose, safety and tolerability of vorinostat plus decitabine in patients with relapsed/refractory AML, newly-diagnosed AML, or intermediate- to high-grade MDS. Thirty-four patients received concurrent therapy with decitabine plus vorinostat and 37 received sequential therapy with decitabine followed by vorinostat. Twenty-nine patients had relapsed/refractory AML, 31 had untreated AML and 11 had MDS. The target maximum administered dose (MAD) of decitabine 20 mg/m2 daily for 5 d plus vorinostat 400 mg/d for 14 d was achieved for concurrent and sequential schedules, with one dose-limiting toxicity (Grade 3 QTc prolongation) reported in the sequential arm. Common toxicities were haematological and gastrointestinal. Responses were observed more frequently at the MAD on the concurrent schedule compared with the sequential schedule in untreated AML (46{\%} vs. 14{\%}), relapsed/refractory AML (15{\%} vs. 0{\%}) and MDS (60{\%} vs. 0{\%}). Decitabine plus vorinostat given concurrently or sequentially appears to be safe and well-tolerated. Concurrent therapy shows promising clinical activity in AML or MDS, warranting further investigation.",
keywords = "Acute myeloid leukaemia, Combination therapy, Decitabine, Myelodysplastic syndrome, Vorinostat",
author = "Mark Kirschbaum and Ivana Gojo and Goldberg, {Stuart L.} and Christopher Bredeson and Kujawski, {Lisa A.} and Allen Yang and Peter Marks and Paul Frankel and Xing Sun and Alessandra Tosolini and Eid, {Joseph E.} and Lubiniecki, {Gregory M.} and Issa, {Jean Pierre}",
year = "2014",
month = "10",
day = "1",
doi = "10.1111/bjh.13016",
language = "English (US)",
volume = "167",
pages = "185--193",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

AU - Kirschbaum, Mark

AU - Gojo, Ivana

AU - Goldberg, Stuart L.

AU - Bredeson, Christopher

AU - Kujawski, Lisa A.

AU - Yang, Allen

AU - Marks, Peter

AU - Frankel, Paul

AU - Sun, Xing

AU - Tosolini, Alessandra

AU - Eid, Joseph E.

AU - Lubiniecki, Gregory M.

AU - Issa, Jean Pierre

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) may respond to treatment with epigenetic-modifying agents. Histone deacetylase inhibitors may synergize with hypomethylating agents. This phase 1 dose-escalation study was designed to determine the maximum tolerated dose, recommended phase 2 dose, safety and tolerability of vorinostat plus decitabine in patients with relapsed/refractory AML, newly-diagnosed AML, or intermediate- to high-grade MDS. Thirty-four patients received concurrent therapy with decitabine plus vorinostat and 37 received sequential therapy with decitabine followed by vorinostat. Twenty-nine patients had relapsed/refractory AML, 31 had untreated AML and 11 had MDS. The target maximum administered dose (MAD) of decitabine 20 mg/m2 daily for 5 d plus vorinostat 400 mg/d for 14 d was achieved for concurrent and sequential schedules, with one dose-limiting toxicity (Grade 3 QTc prolongation) reported in the sequential arm. Common toxicities were haematological and gastrointestinal. Responses were observed more frequently at the MAD on the concurrent schedule compared with the sequential schedule in untreated AML (46% vs. 14%), relapsed/refractory AML (15% vs. 0%) and MDS (60% vs. 0%). Decitabine plus vorinostat given concurrently or sequentially appears to be safe and well-tolerated. Concurrent therapy shows promising clinical activity in AML or MDS, warranting further investigation.

AB - Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) may respond to treatment with epigenetic-modifying agents. Histone deacetylase inhibitors may synergize with hypomethylating agents. This phase 1 dose-escalation study was designed to determine the maximum tolerated dose, recommended phase 2 dose, safety and tolerability of vorinostat plus decitabine in patients with relapsed/refractory AML, newly-diagnosed AML, or intermediate- to high-grade MDS. Thirty-four patients received concurrent therapy with decitabine plus vorinostat and 37 received sequential therapy with decitabine followed by vorinostat. Twenty-nine patients had relapsed/refractory AML, 31 had untreated AML and 11 had MDS. The target maximum administered dose (MAD) of decitabine 20 mg/m2 daily for 5 d plus vorinostat 400 mg/d for 14 d was achieved for concurrent and sequential schedules, with one dose-limiting toxicity (Grade 3 QTc prolongation) reported in the sequential arm. Common toxicities were haematological and gastrointestinal. Responses were observed more frequently at the MAD on the concurrent schedule compared with the sequential schedule in untreated AML (46% vs. 14%), relapsed/refractory AML (15% vs. 0%) and MDS (60% vs. 0%). Decitabine plus vorinostat given concurrently or sequentially appears to be safe and well-tolerated. Concurrent therapy shows promising clinical activity in AML or MDS, warranting further investigation.

KW - Acute myeloid leukaemia

KW - Combination therapy

KW - Decitabine

KW - Myelodysplastic syndrome

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=84908555755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908555755&partnerID=8YFLogxK

U2 - 10.1111/bjh.13016

DO - 10.1111/bjh.13016

M3 - Article

C2 - 25040094

AN - SCOPUS:84908555755

VL - 167

SP - 185

EP - 193

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -